EcoDrugPlus

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSPMRG00000005808
Gene Symbol: YES1
1 Cross references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSPMRG00000023193
Gene Symbol: ACHE
1 Cross references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Activin A Receptor Type 2b

Ensembl ID : ENSPMRG00000011898
Gene Symbol: ACVR2B
3 Cross references
257 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A1 Receptor

Ensembl ID : ENSPMRG00000003805
Gene Symbol: ADORA1
3 Cross references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A2a Receptor

Ensembl ID : ENSPMRG00000017382
Gene Symbol: ADORA2A
3 Cross references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A2b Receptor

Ensembl ID : ENSPMRG00000023630
Gene Symbol: ADORA2B
1 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine Deaminase

Ensembl ID : ENSPMRG00000008678
Gene Symbol: ADA
1 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine Receptor A3-Like

Ensembl ID : ENSPMRG00000006083
Gene Symbol: LOC114599925
2 Cross references
88 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine Receptor A3-Like

Ensembl ID : ENSPMRG00000006087
Gene Symbol: LOC114599363
2 Cross references
86 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 1a

Ensembl ID : ENSPMRG00000014316
Gene Symbol: ADRA1A
3 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 1d

Ensembl ID : ENSPMRG00000009736
Gene Symbol: ADRA1D
3 Cross references
194 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 2a

Ensembl ID : ENSPMRG00000002940
Gene Symbol: ADRA2A
1 Cross references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).